Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction. This promising new therapeutic approach is known as adoptive cell therapy.
CD22 is a cell surface protein expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma. Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins. This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptive cell therapy treatment for cancer.
Competitive Advantages:
- High affinity of the m971 antibody binding fragment increases the likelihood of successful targeting
- Targeted therapy decreases non-specific killing of healthy, essential cells, potentially resulting in fewer non-specific side-effects and healthier patients
- Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream
- Expression of CD22 only on mature cells avoids stem cell elimination during treatment
Commercial Applications:
- Treatment of diseases associated with increased or preferential expression of CD22
- Hematological cancers such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (ALL)
Related Inventions
-
E-017-2017
TAB-4017
Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs) -
E-080-2008
TAB-4346
Human and Improved Murine Monoclonal Antibodies Against CD22 -
E-106-2015
TAB-4268
Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs) -
E-161-2018
TAB-3892
Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Patents
- US
Provisional (PRV) 61/717,960
Filed on 2012-10-24
Status: Abandoned - Patent Cooperation Treaty
(PCT) PCT/US2013/060332
Filed on 2013-09-18
Status: Expired - Australia
National Stage 2013335180
Filed on 2013-09-18
Status: Issued - Brazil
National Stage BR112015009003-6
Filed on 2015-04-22
Status: Issued - Canada
National Stage 2889055
Filed on 2013-09-18
Status: Issued - China
National Stage 201380061387.5
Filed on 2015-05-25
Status: Issued - European Patent
National Stage 13773468.7
Filed on 2013-09-18
Status: Issued - India
National Stage 2344/CHENP/2015
Filed on 2013-09-18
Status: Issued - Japan
National Stage 2015-539602
Filed on 2013-09-18
Status: Issued - Russia
National Stage 2015117237
Filed on 2015-05-07
Status: Issued - US Patent 10,072,078
Filed on 2015-04-23
Status: Issued - Hong Kong
National Stage 16101891.0
Filed on 2016-02-19
Status: Issued - Russia
Divisional (DIV) 2018116582
Filed on 2018-05-04
Status: Issued - Japan
Divisional (DIV) 2018-088908
Filed on 2018-05-02
Status: Issued - Australia
Divisional (DIV) 2018204257
Filed on 2018-06-14
Status: Issued - US Patent 10,703,816
Filed on 2018-08-21
Status: Issued - Germany
European patent (EP) 13773468.7
Filed on 2015-04-22
Status: Issued - Spain
European patent (EP) 13773468.7
Filed on 2015-04-22
Status: Issued - France
European patent (EP) 13773468.7
Filed on 2015-04-22
Status: Issued - United Kingdom
European patent (EP) 13773468.7
Filed on 2015-04-22
Status: Issued - Italy
European patent (EP) 13773468.7
Filed on 2015-04-22
Status: Issued - China
Divisional (DIV) 201910500128.7
Filed on 2019-06-11
Status: Issued - US Patent 11,807,682
Filed on 2020-05-08
Status: Issued
Collaborations
- Licensing
- Collaboration